Sort by
Items per page

Send to

Choose Destination

Search results

Items: 14


Host-Microbe Interactions in Airway Disease: toward Disease Mechanisms and Novel Therapeutic Strategies.

Cope EK.

mSystems. 2018 Mar 13;3(2). pii: e00158-17. doi: 10.1128/mSystems.00158-17. eCollection 2018 Mar-Apr.


Fungal Microbiota in Chronic Airway Inflammatory Disease and Emerging Relationships with the Host Immune Response.

Zhang I, Pletcher SD, Goldberg AN, Barker BM, Cope EK.

Front Microbiol. 2017 Dec 12;8:2477. doi: 10.3389/fmicb.2017.02477. eCollection 2017.


Compositionally and functionally distinct sinus microbiota in chronic rhinosinusitis patients have immunological and clinically divergent consequences.

Cope EK, Goldberg AN, Pletcher SD, Lynch SV.

Microbiome. 2017 May 12;5(1):53. doi: 10.1186/s40168-017-0266-6.


Mapping and comparing bacterial microbiota in the sinonasal cavity of healthy, allergic rhinitis, and chronic rhinosinusitis subjects.

Lal D, Keim P, Delisle J, Barker B, Rank MA, Chia N, Schupp JM, Gillece JD, Cope EK.

Int Forum Allergy Rhinol. 2017 Jun;7(6):561-569. doi: 10.1002/alr.21934. Epub 2017 May 8.


A chronic rhinosinusitis-derived isolate of Pseudomonas aeruginosa induces acute and pervasive effects on the murine upper airway microbiome and host immune response.

Cope EK, Goldberg AN, Pletcher SD, Lynch SV.

Int Forum Allergy Rhinol. 2016 Dec;6(12):1229-1237. doi: 10.1002/alr.21819. Epub 2016 Sep 6.


Evaluation of Malassezia and Common Fungal Pathogens in Subtypes of Chronic Rhinosinusitis.

Gelber JT, Cope EK, Goldberg AN, Pletcher SD.

Int Forum Allergy Rhinol. 2016 Sep;6(9):950-5. doi: 10.1002/alr.21777. Epub 2016 May 6.


Novel microbiome-based therapeutics for chronic rhinosinusitis.

Cope EK, Lynch SV.

Curr Allergy Asthma Rep. 2015 Mar;15(3):504. doi: 10.1007/s11882-014-0504-y.


Sub-inhibitory fosmidomycin exposures elicits oxidative stress in Salmonella enterica serovar Typhimurium LT2.

Fox DT, Schmidt EN, Tian H, Dhungana S, Valentine MC, Warrington NV, Phillips PD, Finney KB, Cope EK, Leid JG, Testa CA, Koppisch AT.

PLoS One. 2014 Apr 21;9(4):e95271. doi: 10.1371/journal.pone.0095271. eCollection 2014.


Probiotic strategies for treatment of respiratory diseases.

Nagalingam NA, Cope EK, Lynch SV.

Trends Microbiol. 2013 Sep;21(9):485-92. doi: 10.1016/j.tim.2013.04.008. Epub 2013 May 23. Review.


Regulation of virulence gene expression resulting from Streptococcus pneumoniae and nontypeable Haemophilus influenzae interactions in chronic disease.

Cope EK, Goldstein-Daruech N, Kofonow JM, Christensen L, McDermott B, Monroy F, Palmer JN, Chiu AG, Shirtliff ME, Cohen NA, Leid JG.

PLoS One. 2011;6(12):e28523. doi: 10.1371/journal.pone.0028523. Epub 2011 Dec 5.


In vitro antimicrobial studies of silver carbene complexes: activity of free and nanoparticle carbene formulations against clinical isolates of pathogenic bacteria.

Leid JG, Ditto AJ, Knapp A, Shah PN, Wright BD, Blust R, Christensen L, Clemons CB, Wilber JP, Young GW, Kang AG, Panzner MJ, Cannon CL, Yun YH, Youngs WJ, Seckinger NM, Cope EK.

J Antimicrob Chemother. 2012 Jan;67(1):138-48. doi: 10.1093/jac/dkr408. Epub 2011 Oct 3.


Tobacco smoke mediated induction of sinonasal microbial biofilms.

Goldstein-Daruech N, Cope EK, Zhao KQ, Vukovic K, Kofonow JM, Doghramji L, González B, Chiu AG, Kennedy DW, Palmer JN, Leid JG, Kreindler JL, Cohen NA.

PLoS One. 2011 Jan 6;6(1):e15700. doi: 10.1371/journal.pone.0015700.


Flagellum-mediated biofilm defense mechanisms of Pseudomonas aeruginosa against host-derived lactoferrin.

Leid JG, Kerr M, Selgado C, Johnson C, Moreno G, Smith A, Shirtliff ME, O'Toole GA, Cope EK.

Infect Immun. 2009 Oct;77(10):4559-66. doi: 10.1128/IAI.00075-09. Epub 2009 Aug 3.


Supplemental Content

Support Center